Prevalence of seropositivity to spotted fever group rickettsiae and Anaplasma phagocytophilum in a large, demographically diverse US sample

Clinical Infectious Diseases

Volumn 46, Issue 1, 2008, Pages 70-77

  Graf, Paul C F ^a   Chretien, Jean Paul ^b   Ung, Lady ^a   Gaydos, Joel C ^b   Richards, Allen L ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Department of Defense Global Emerging Infections Surveillance and Response System ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICAN AMERICAN; ANAPLASMA PHAGOCYTOPHILUM; ANAPLASMOSIS; ARMY; ARTICLE; CONFIDENCE INTERVAL; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPEAN AMERICAN; FEMALE; HUMAN; INCIDENCE; INFECTION RISK; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RICKETTSIA; RISK ASSESSMENT; RISK FACTOR; ROCKY MOUNTAIN SPOTTED FEVER; SEROPREVALENCE; SEX DIFFERENCE; SOLDIER; UNITED STATES; UNIVARIATE ANALYSIS; WESTERN BLOTTING;

ADULT; ANAPLASMA PHAGOCYTOPHILUM; BLOTTING, WESTERN; CROSS-SECTIONAL STUDIES; EHRLICHIOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MILITARY PERSONNEL; PREVALENCE; RICKETTSIA RICKETTSII; ROCKY MOUNTAIN SPOTTED FEVER; SEROEPIDEMIOLOGIC STUDIES; UNITED STATES;

EID: 39349113995     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/524018     Document Type: Article

References (29)

1. Chapman AS, Murphy SM, Demma LJ, et al. Rocky Mountain spotted fever in the United States, 1997-2002. Vector Borne Zoonotic Dis 2006; 6:170-8.
2. Demma LJ, Holman RC, McQuiston JH, Krebs JW, Swerdlow DL. Epidemiology of human ehrlichiosis and anaplasmosis in the United States, 2001-2002. Am J Trop Med Hyg 2005; 73:400-9.
3. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis - United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1-27.
4. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever, 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995; 52:405-13.
5. Finley RW, Goddard J, Raoult D, Eremeeva ME, Cox RD, Paddock CD. Rickettsia parkeri: a case of tick-borne, echar-associated spotted fever in Mississippi [abstract 188]. In: Program and abstracts of the 5th International Conference on Emerging Infectious Diseases (Atlanta). Atlanta, GA: Centers for Disease Control and Prevention, 2006: 110.
6. Paddock CD, Sumner JW, Comer JA, et al. Rickettsia parkeri: a newly recognized cause of spotted fever rickettsiosis in the United States. Clin Infect Dis 2004; 38:805-11.
7. Whitman TJ, Richards AL, Paddock CD, et al. Rickettsia parkeri infection after tick bite, Virginia. Emerg Infect Dis 2007; 13:334-6.
8. Paddock CD. Rickettsia parkeri as a paradigm for multiple causes of tick-borne spotted fever in the western hemisphere. Ann N Y Acad Sci 2005; 1063:315-26.
9. Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agen' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51:2145-65.
10. Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005; 11:1828-34.
11. Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci 2005; 1063:361-73.
12. Barker TL, Richards AL, Laksono E, et al. Serosurvey of Borrelia burgdorferi infection among U.S. military personnel: a low risk of infection. Am J Trop Med Hyg 2001; 65:804-9.
13. Ge H, Chuang YY, Zhao S, et al. Comparative genomics of Rickettsia prowazekii Madrid E and Breinl strains. J Bacteriol 2004; 186:556-65.
14. Marshall GS, Stout GG, Jacobs RF, et al. Antibodies reactive to Rickettsia rickettsii among children living in the southeast and south central regions of the United States. Arch Pediatr Adolesc Med 2003; 157:443-8.
15. Taylor JP, Tanner WB, Rawlings JA, et al. Serological evidence of subclinical Rocky Mountain spotted fever infections in Texas. J Infect Dis 1985; 151:367-9.
16. McCall CL, Curns AT, Rotz LD, et al. Fort Chaffee revisited: the epidemiology of tick-borne rickettsial and ehrlichial diseases at a natural focus. Vector Borne Zoonotic Dis 2001; 1:119-27.
17. Yevich SJ, Sanchez JL, DeFraites RF, et al. Seroepidemiology of infections due to spotted fever group rickettsiae and Ehrlichia species in military personnel exposed in areas of the United States where such infections are endemic. J Infect Dis 1995; 171:1266-73.
18. Raoult D, Paddock CD. Rickettsia parkeri infection and other spotted fevers in the United States. N Engl J Med 2005; 353:626-7.
19. Eremeeva ME, Bosserman EA, Demma LJ, Zambrano ML, Blau DM, Dasch GA. Isolation and identification of Rickettsia massiliae from Rhipicephalus sanguineus ticks collected in Arizona. Appl Environ Microbiol 2006; 72:5569-77.
20. Aguero-Rosenfeld ME, Donnarumma L, Zentmaier L, et al. Seroprevalence of antibodies that react with Anaplasma phagocytophila, the agent of human granulocytic ehrlichiosis, in different populations in Westchester County, New York. J Clin Microbiol 2002; 40:2612-5.
21. Ravyn MD, Goodman JL, Kodner CB, et al. Immunodiagnosis of human granulocytic ehrlichiosis by using culture-derived human isolates. J Clin Microbiol 1998; 36:1480-8.
22. Sanchez JL, Candler WH, Fishbein DB, et al. A cluster of tick-borne infections: association with military training and asymptomatic infections due to Rickettsia rickettsii. Trans R Soc Trop Med Hyg 1992; 86:321-5.
23. Hilton E, DeVoti J, Benach JL, et al. Seroprevalence and seroconversion for tick-borne diseases in a high-risk population in the northeast United States. Am J Med 1999; 106:404-9.
24. Bakken JS, Goellner P, Van Etten M, et al. Seroprevalence of human granulocytic ehrlichiosis among permanent residents of northwestern Wisconsin. Clin Infect Dis 1998; 27:1491-6.
25. Woessner R, Gaertner BC, Grauer MT, et al. Incidence and prevalence of infection with human granulocytic ehrlichiosis agent in Germany: a prospective study in young healthy subjects. Infection 2001; 29:271-3.
26. Aguero-Rosenfeld ME, Kalantarpour F, Baluch M, et al. Serology of culture-confirmed cases of human granulocytic ehrlichiosis. J Clin Microbiol 2000; 38:635-8.
27. Bakken JS, Krueth J, Wilson-Nordskog C, Tilden RL, Asanovich K, Dumler JS. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275:199-205.
28. Bakken JS, Haller I, Riddell D, Walls JJ, Dumler JS. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34:22-7.
29. Raoult D. A new rickettsial disease in the United States. Clin Infect Dis 2004; 38:812-3.